Retatrutide, Tirzepatide, and Semaglutide are the three GLP-1-pathway compounds dominating both pharmaceutical weight-loss treatment and research-peptide search interest. They are not interchangeable: each targets a different combination of metabolic receptors, with meaningfully different trial results. Here is how they actually compare.
The Core Difference: Receptor Targets
| Compound | Receptor Targets | Mechanism Class |
|---|---|---|
| Semaglutide | GLP-1 | Single agonist |
| Tirzepatide | GLP-1 + GIP | Dual agonist |
| Retatrutide | GLP-1 + GIP + Glucagon | Triple agonist |
Semaglutide activates a single receptor pathway. Tirzepatide adds GIP receptor activity alongside GLP-1. Retatrutide goes a step further, adding glucagon receptor agonism on top of both — the glucagon component is specifically associated with increased energy expenditure and fat oxidation, not just appetite suppression, which is why it is mechanistically distinct from the other two rather than simply "stronger."
What the Trial Data Shows
Each compound has been studied at different trial stages, so results are not perfectly comparable, but the reported trends are consistent with their mechanism differences:
- Semaglutide (the compound behind Ozempic/Wegovy) has the longest real-world and trial track record among the three, with the most mature safety dataset.
- Tirzepatide (the compound behind Mounjaro/Zepbound) has shown greater average weight reduction than semaglutide in head-to-head trial data, consistent with its added GIP activity.
- Retatrutide is earlier in clinical development (Phase 2 completed) but has shown the largest reported weight reduction of the three in trial data to date, with no plateau observed at 48 weeks in its Phase 2 study — the triple-agonist mechanism appears to translate into a materially different response curve, though Phase 3 data will be the real test.
Research Status
Semaglutide and Tirzepatide are FDA-approved pharmaceutical compounds (for their respective approved indications) with established prescription pathways. Retatrutide remains an investigational compound, not yet FDA- or EMA-approved, and is currently supplied only as a research compound. All three, in research-grade form, are supplied strictly for in-vitro laboratory and research use only, not for human consumption.
Frequently Asked Questions
Is Retatrutide stronger than Tirzepatide? Reported trial data shows greater average weight reduction with Retatrutide, consistent with its additional glucagon receptor mechanism, but Retatrutide is earlier in clinical development (Phase 2) versus Tirzepatide's approved status. Direct head-to-head Phase 3 data will give a clearer comparison.
What's the difference between a dual and triple agonist? A dual agonist (Tirzepatide) activates two receptor pathways (GLP-1 and GIP). A triple agonist (Retatrutide) activates three (GLP-1, GIP, and glucagon) — the added glucagon activity is linked to increased energy expenditure, not just appetite suppression.
Are these compounds available as research peptides? Yes, research-grade versions of all three are available for laboratory and research use. See our Retatrutide product page for detailed mechanism data, and our Retatrutide Price Guide for current market pricing.
Where can I buy verified research peptides? Through an OnlinePeptides authorized reseller. Check our Store Network or Verify a Reseller before purchasing from any source claiming to carry our products.
Disclaimer: This article is for research and educational purposes only. Retatrutide, Tirzepatide, and Semaglutide research-grade peptides are supplied strictly for in-vitro laboratory and research use, not for human consumption or therapeutic use. Semaglutide and Tirzepatide are approved pharmaceutical compounds under their respective brand names when prescribed by a licensed physician; this article does not constitute medical advice. Regulatory treatment varies by jurisdiction.
